Download Full Text (4.1 MB)
- Chronic Myelogenous Leukemia: Refining Approaches to Treatment
- Advancing the Treatment of Lymphedema
- House Call: Hospice: Comforting Care When the End Is Near
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
The University of Texas MD Anderson Cancer Center
Cortes, Jorge E.; Kantarjian, Hagop, 1952-; Arlinghaus, Ralph B.; Chang, David W. (Plastic surgeon); Kopetz, Scott; Chambers, Mark S.; Garcia, M. Kay; Suami, Hiroo; Leukemia, Myeloid, Chronic-Phase; Imatinib Mesylate; Tyrosine Protein Kinase Inhibitors; Survival Rate; Philadelphia Chromosome; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Fusion Proteins, bcr-abl; Genes, abl; Dasatinib; Protein-Tyrosine Kinases; nilotinib; bosutinib; Clinical Trials, Phase II as Topic; ponatinib; Antineoplastic Agents; DCC-2036; Quinolines; danusertib; src-Family Kinases; Clinical Trials as Topic; Lymphedema; Manual Lymphatic Drainage; Lymphatic System; Colorectal Neoplasms -- secondary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Acupuncture Therapy; Xerostomia; Radiotherapy -- adverse effects; Clinical Trials, Phase III as Topic; Pilocarpine; Hospice Care; Respite Care; Palliative Care; Janus Kinase 2; Cancer Vaccines.
History of Science, Technology, and Medicine | Oncology
LeBas, John and Veech, Maude, "OncoLog Volume 54, Number 6, June 2009" (2009). OncoLog MD Anderson's Report to Physicians (All issues). 199.
Conditions Governing Access